Predictors of vaginal @entity850 after intravaginal high-dose-rate brachytherapy for XXXX .

@entity1204 @entity1 @entity5 @entity8376 @entity850
PURPOSE: Intravaginal high-dose-rate brachytherapy is an effective adjuvant treatment for localized @entity1204 . However, relatively little is known about risk factors of post-treatment vaginal @entity850 (VS). METHODS AND MATERIALS: We included @entity1 treated with brachytherapy for @entity1204 from September 2011 to January 2014 with at least 3 months of followup. @entity1 who received external beam radiation therapy were excluded. VS was prospectively graded at each followup visit per Common Terminology Criteria for Adverse Events, version 4.03.   (2) and t test analyses were used to assess the association of VS with various @entity1 , @entity5 , treatment, and post-treatment factors. Multivariable logistic regression analysis was used to identify independent predictors of VS Grade >= 1 and >= 2. RESULTS: All 101 @entity1 were disease free at last followup. Mean followup was 12.9 months (range, 3-34). Highest VS grades were zero in 67%, one in 26%, two in 6%, and three in 1%. Borderline significant variables associated with Grade >= 1 VS included @entity8376 , proportion of vagina treated, and total dose. Dilator use was significantly associated with Grade >= 2. Multivariable analysis revealed that proportion of vagina treated >60% (odds ratio [OR], 3.48; p = 0.009) and total dose >14 Gy (OR, 4.27; p = 0.015) were independent predictors of Grade >= 1 VS, and lack of consistent dilator use was an independent predictor of Grade >= 2 VS (OR, 5.60; p = 0.047). CONCLUSIONS: @entity1 treated with a higher total dose to a larger proportion of the vagina were more likely to develop Grade >= 1 VS. Consistent dilator use may also be protective against Grade >= 2 VS.
